Agnieszka Gliwa, MD
Endocrinology, Diabetes & Metabolism · Brooklyn, NYNPI 1487649919
Payments from drug & device makers
Across 184 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amneal Pharmaceuticals LLC$511
- Exact Sciences$478
- AbbVie$349
- Lilly USA, LLC$243
- Astellas Pharma US Inc$216
- AstraZeneca$184
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,89699%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amneal Pharmaceuticals LLC | 30 | $511 |
| Exact Sciences | 17 | $478 |
| AbbVie | 18 | $349 |
| Lilly USA, LLC | 11 | $243 |
| Astellas Pharma US Inc | 8 | $216 |
| AstraZeneca(2 entities) | 11 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $152 |
| Amarin Pharma, Inc. | 7 | $151 |
| Amgen | 8 | $139 |
| Novo Nordisk | 6 | $133 |
| Corcept Therapeutics | 5 | $128 |
| Bayer | 1 | $125 |
| Boehringer Ingelheim | 5 | $107 |
| Tandem Diabetes Care, Inc. | 4 | $107 |
| Medtronic | 1 | $96 |
| Biohorizons Implant Systems Inc. | 1 | $89 |
| Dexcom, Inc. | 4 | $84 |
| Merck | 5 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $75 |
| Amryt Pharma Holdings Ltd | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Eisai Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $34 |
| Insulet Corporation | 2 | $27 |
| Biomarin Pharmaceutical Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| BETA Bionics, Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Renalytix AI, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $15 |
| Vistapharm, Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
How this compares
$3,926 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 340 | $482,983 |
| JardianceEmpagliflozin | 312 | $359,036 |
| JanumetSitagliptin Phos/Metformin Hcl | 208 | $193,849 |
| JanuviaSitagliptin Phosphate | 158 | $169,025 |
| MounjaroTirzepatide | 98 | $115,173 |
| FarxigaDapagliflozin Propanediol | 84 | $92,565 |
| TrulicityDulaglutide | 52 | $72,359 |
| SynjardyEmpagliflozin/Metformin Hcl | 41 | $42,426 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 121 | $41,580 |
| TradjentaLinagliptin | 37 | $40,040 |
| XareltoRivaroxaban | 23 | $35,127 |
| Novolog FlexpenInsulin Aspart | 147 | $30,456 |
| KerendiaFinerenone | 18 | $30,267 |
| Repatha SureclickEvolocumab | 27 | $29,831 |
| Victoza 3-PakLiraglutide | 23 | $27,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Novolog | $133 | $507,447375 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Jentadueto | $107 | $465,336424 claims |
| MerckJanumet, Januvia, Janumet Xr | $78 | $386,464398 claims |
| Lilly USA, LLCMounjaro, Trulicity | $243 | $187,532150 claims |
| AstraZenecaFarxiga | $184 | $92,56584 claims |
| Johnson & JohnsonXarelto | $34 | $35,12723 claims |
| BayerKerendia | $125 | $30,26718 claims |
| AmgenProlia | $139 | $22,99314 claims |
| PfizerEliquis | $19 | $21,07214 claims |
| NovartisEntresto | $12 | $18,75514 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $48 | $8,35912 claims |
| AbbVieSynthroid | $349 | $6,853108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Brooklyn
- Robert SilverBrooklyn$1.3M
- Alexander PerkelvaldBrooklyn$323K
- John LeffBrooklyn$248K
- Matvey BrokhinBrooklyn$243K
- Matin SharafatkhahBrooklyn$235K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.